Ovarian Cancer Drugs Market to Witness Robust Expansion throughout 2026
Ovarian Cancer Drugs Market – Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
Ovarian cancer is a relatively rare cancer as compared to other types, though risk is higher among women who have ovulated more over their lifetime, which can also include females who have never borne a child and those who began ovulating at a very young age. According to American Cancer Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in BRCA1 or BRCA2 genes have 50% chance of developing breast or ovarian cancer. Ovarian carcinoma, is the most common ovarian cancer that accounts for 95% of cases, globally.
Request a Sample Copy @ https://www.coherentmarketinsights.com/
Ovarian cancer drugs market supported by growing aging population in the U.S. and U.K.
Rising number of ovarian cancer cases recorded over the recent past, is creating a highly conducive environment for growth of the ovarian cancer drugs market. According to American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3% of the incidence rate, and 2.4% of all related deaths, in 2016.
Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K.
Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to presence of major players and adoption of advanced medical technologies in countries such as the U.S. and Canada. According to American Cancer Society, an estimated 22,440 women would receive a new diagnosis of ovarian cancer and around 14,080 women will die from ovarian cancer in 2017 in the U.S. alone. Ovarian cancer is the fifth most prevalent cancer among women, which accounts for high percentage of deaths when compared to other cancer related to reproductive system cancer.
Combinational drug approach, a novel approach in the ovarian cancer drugs market
Key players operating in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd.
Ovarian Cancer Drugs Market Taxonomy
The global ovarian cancer drugs market is segmented on the basis of chemotherapy drugs, end user, and geography.
On the basis of chemotherapy drugs, the ovarian cancer drugs are segmented into:
• Other Medication (Cyclophosphamide, Doxorubicin, Gemcitabine, Oxaliplatin, and Topotecan).
For More Information, Browse Complete Report Here: https://www.coherentmarketinsights.com/
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154